http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ#Head http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ#assertion http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ#provenance http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ#pubInfo http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ#assertion http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ#assertion http://www.w3.org/ns/prov#wasGeneratedBy S&T TWOC project version 1 http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ#version http://www.w3.org/ns/prov#value 1 http://www.w3.org/1999/02/22-rdf-syntax-ns#object https://uts.nlm.nih.gov/uts/umls/concept/C0013227 drugs http://www.w3.org/1999/02/22-rdf-syntax-ns#object https://uts.nlm.nih.gov/uts/umls/concept/C0021764 interleukin http://www.w3.org/1999/02/22-rdf-syntax-ns#object https://uts.nlm.nih.gov/uts/umls/concept/C0245109 anakinra http://www.w3.org/1999/02/22-rdf-syntax-ns#object https://uts.nlm.nih.gov/uts/umls/concept/C1299393 moderate to severe http://www.w3.org/1999/02/22-rdf-syntax-ns#object https://uts.nlm.nih.gov/uts/umls/concept/C1513853 non http://www.w3.org/1999/02/22-rdf-syntax-ns#object https://uts.nlm.nih.gov/uts/umls/concept/C1527200 interleukin http://www.w3.org/1999/02/22-rdf-syntax-ns#object https://uts.nlm.nih.gov/uts/umls/concept/C1533148 cases http://www.w3.org/1999/02/22-rdf-syntax-ns#object https://uts.nlm.nih.gov/uts/umls/concept/C1609165 tocilizumab http://www.w3.org/1999/02/22-rdf-syntax-ns#object https://uts.nlm.nih.gov/uts/umls/concept/C1609931 siltuximab http://www.w3.org/1999/02/22-rdf-syntax-ns#object https://uts.nlm.nih.gov/uts/umls/concept/C3687832 drugs http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate http://twoc-nlp-database-server-1:8555/solr/predicates/select?q=TRIPLE_UID:pq34mfzt-TRIPLE-ABSTRACT-2 be http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://uts.nlm.nih.gov/uts/umls/concept/C0011777 dexamethasone http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://uts.nlm.nih.gov/uts/umls/concept/C0178602 dose http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://uts.nlm.nih.gov/uts/umls/concept/C0205251 low http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://uts.nlm.nih.gov/uts/umls/concept/C0869039 dose http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://uts.nlm.nih.gov/uts/umls/concept/C1550472 low http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://uts.nlm.nih.gov/uts/umls/concept/C1611820 low http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://uts.nlm.nih.gov/uts/umls/concept/C1619811 low http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://uts.nlm.nih.gov/uts/umls/concept/C2700150 low http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://uts.nlm.nih.gov/uts/umls/concept/C3890211 low http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://uts.nlm.nih.gov/uts/umls/concept/C4048187 low http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://uts.nlm.nih.gov/uts/umls/concept/C4321351 low http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://uts.nlm.nih.gov/uts/umls/concept/C4522223 low http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://uts.nlm.nih.gov/uts/umls/concept/C5203106 low http://www.w3.org/2000/01/rdf-schema#Triple-UID http://twoc-nlp-database-server-1:8555/solr/triples/select?q=TRIPLE_UID:pq34mfzt-TRIPLE-ABSTRACT-2 pq34mfzt-TRIPLE-ABSTRACT-2 http://www.w3.org/2000/01/rdf-schema#sentence http://www.w3.org/2000/01/rdf-schema#label To target the inflammatory cascade, low-dose dexamethasone appears to be helpful in moderate to severe cases and trials with anti-interleukin agents (e.g., tocilizumab, anakinra, siltuximab) and non-steroidal anti-inflammatory drugs are showing early promising results. http://www.w3.org/2000/01/rdf-schema#triple http://www.w3.org/2000/01/rdf-schema#label low - dose dexamethasone be in moderate to severe cases and trials with anti - interleukin agents ( e.g. , tocilizumab , anakinra , siltuximab ) and non - steroidal anti - inflammatory drugs http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ#provenance http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ#assertion http://www.w3.org/ns/prov#generatedAtTime 2021-07-25T21:46:20.879852 http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ#pubInfo http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCSLeezU8JYlBsrgXOGXX4fxOq4oydsMzMK1CN0Rez2OEd2IYk18R4DetcZXwGhN3Pil7qcgNkiGvTirJXIo8zHl7jVehs19EdYtrttCKEaXRzWIr4LuCrfGedkvonEMWqR8e1GdQsLgEEyM50BD6Qw+srQt9ozcqf/9wG2MAMX9QIDAQAB http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ#sig http://purl.org/nanopub/x/hasSignature ZappbXqFom74kzqytuyy81GX87uQV1IZTWGtOc/KNsnEuF/H7ivtcu4vMTEa7vZACiqOQR+4JR/r+p7kUEfFWvfKuITyKbNp9unIQVcxtJWtoig6qr1YBejcDjHN9Wc0fHh0uDndYwgq6QM+Z+B1uwZ8z+U4eyHRdWmNau3VZmA= http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ http://www.w3.org/ns/prov#generatedAtTime 2021-07-25T21:46:20.879852 http://purl.org/np/RAA1Zw8C9_dO5El4QXi5RIcnJqm2YlMmjL5QATX1yJGiQ http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-8954-0470